Assistant Professor, Department of Pharmaceutical and Pathology
University of South Florida, USA
Dr. Jiazhi Sun has been trained in the field of basic medical science and molecular biology and received M.D. degree from Peking University in 1986. After completing his residency and fellowship training at Peking University in 1990 and graduate studies on targeting Q-binding protein into yeast mitochondria at West Virginia University in 1994, he received two-terms postdoc training at the University of Pittsburgh and H. Lee Moffitt Cancer Center in the field of Pharmacology, Biochemistry and Drug Discovery from 1994 to 2003.
Dr. Jiazhi Sun focuses on Ras and ER signaling study, HDL-Receptor RNA alternative processing, and K-Ras, GPCR, BH3 protein and VDR/ER drug discovery targeting by utilizing Target-Guided Synthesis (TGS) approach and conventional intervention. Dr. Sun has more than 18-year professional experience in academic field including Drug Discovery, Signal Transduction, Apoptosis, Cancer Biology and Cardiovascular field, also leading collaborative Institutional and Pharmaceutical Industry rational design/targeted-therapeutic approach and development of FTI, GGTI and Kinase inhibitors (tyrosine, serine/threonine and sphingosine) and nuclear hormone receptor mimics as well as BH3-mimics as drug candidates and “Chemical-Genetics” tool/model. Since 1994, he has been involved in multiple programs yielding two U.S. patents, more than 30 peer-reviewed papers, book chapter, numerous awards including AFLAC Scholar in Cancer Research Award sponsored by American Association of Cancer Research and more than 30 scientific professional presentations.